Journal of Genetic Syndromes & Gene Therapy
Open Access

Long space missions and gene therapy

International Conference on Genetic Syndromes & Gene Therapy

November 19-21, 2012 Hilton San Antonio Airport, USA

William J. Rowe

Scientific Tracks Abstracts: J Genet Syndr Gene Ther

Abstract :

With microgravity (M) there is invariable malabsorption necessitating subcutaneous (SC) pharmaceuticals (P). With no replenishable SC silicon device available to administer them a therapeutic dilemma exists . Also SC P are limited in number and several P shown to deteriorate with space flight (SF) even in low earth orbit possibly radiation-induced. Liver, kidney functions deteriorate possibly complicating endothelial dysfunction stemming from invariable serum magnesium (Mg.) deficits despite low sensitivity ( p <0.0001) and in turn adrenaline elevations with vicious cycles between the two with in turn inflammation , oxidative stress, mitochondrial injuries.. Other than simulating exactly 1 G. thereby entirely avoiding M complications, there appears to be no alternative except gene therapy (GT) on a limited basis. Suggest beginning with the correction of as many as 4 angiogenesis � related gene deficiencies : (1) atrial natriuretic peptide (ANP) reduced by > 40 % after only 7-12 SF- days stemming partially from Mg. deficits reducing synthesis and release of ANP; (2) nitric oxide (NO); c GMP is a 2nd. messenger of both NO and ANP and is not detectable after 5 months in M (3) vascular endothelial growth factor (VEGF) triggered by SF- thrombocytopenia . Platelets are primary source of VEGF. (4) erythropoietin reduced by about 10 % along with 10 % SF- reductions of plasma volume (PV). Using a PV substitute and a SC device to administer Mg may reduce complexity of GT. If unsuccessful in correcting liver, kidney dysfunctions in order to resume P therapy , additional serial GT will be required.

Biography :

William J. Rowe M.D. (Fellow British Interplanetary Society ) is a board certified specialist in Internal Medicine. He was in private practice in Toledo, Ohio for 34 years. He was the first to publish that extraordinary, unremitting endurance exercise can injure a normal heart. He studied 3 world class extraordinary endurance athletes and published their exercise ?related magnesium deficiencies; this triggered a 20 year pursuit of the cardiovascular complications of Space flight. He published in CIRCULATION a description of only the second Space-related Syndrome. He has been listed in the Marquis Whos Who of the World from 2002-2009